• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Janux Therapeutics

Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease

By Pallavi Madhiraju on February 18, 2026   Pharma & Biotech  

Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease

Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.

Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion

By Pallavi Madhiraju on January 1, 2026   Pharma & Biotech  

Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion

Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.

Recent Posts

  • Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
  • Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
  • Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
  • Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update
  • Orthogon Therapeutics adds $11m for BK virus drug, targeting one of transplant medicine’s toughest gaps
  • LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
  • Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption
  • Khondrion moves sonlicromanol into Phase 3, but can KHENERFIN finally crack mitochondrial disease?
  • Why Bruker’s ESCMID 2026 microbiology expansion could matter for hospital labs and infection control
  • Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
  • Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
  • Why MyGenius PRO could strengthen Bruker’s position in automated infectious disease diagnostics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes